Medincell (XPAR:MEDCL) EBIT per Share : €-0.85 (TTM As of Sep. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Medincell EBIT per Share?

Medincell's EBIT per Share for the six months ended in Sep. 2023 was €-0.21. Its EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 was €-0.85.

During the past 3 years, the average EBIT per Share Growth Rate was 0.20% per year. During the past 5 years, the average EBIT per Share Growth Rate was -8.70% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.

The historical rank and industry rank for Medincell's EBIT per Share or its related term are showing as below:

XPAR:MEDCL' s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -72 Med: -6.3 Max: 0.2
Current: 0.2

During the past 8 years, the highest 3-Year average EBIT per Share Growth Rate of Medincell was 0.20% per year. The lowest was -72.00% per year. And the median was -6.30% per year.

XPAR:MEDCL's 3-Year EBIT Growth Rate is ranked worse than
54.1% of 1305 companies
in the Biotechnology industry
Industry Median: 3.4 vs XPAR:MEDCL: 0.20

Medincell's EBIT for the six months ended in Sep. 2023 was €-5.76 Mil.

Medincell EBIT per Share Historical Data

The historical data trend for Medincell's EBIT per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medincell EBIT per Share Chart

Medincell Annual Data

Trend

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

EBIT per Share

Get a 7-Day Free Trial

-1.02

-0.96

-0.76

-0.92

-1.12

Medincell Semi-Annual Data
	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
EBIT per Share	Get a 7-Day Free Trial										-0.44	-0.48	-0.47	-0.64	-0.21

Medincell EBIT per Share Calculation

EBIT per Share is the amount of Earnings Before Interest and Taxes (EBIT) per outstanding share of the company's stock.

Earnings Before Interest and Taxes (EBIT) is what the company earns before it expenses interest and taxes.

Medincell's EBIT per Share for the fiscal year that ended in Mar. 2023 is calculated as

	EBIT per Share		(A: Mar. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-28.078	/	25.188
=	-1.11

Medincell's EBIT per Share for the quarter that ended in Sep. 2023 is calculated as

	EBIT per Share		(Q: Sep. 2023 )
=	EBIT	/	Shares Outstanding (Diluted Average)
=	-5.759	/	27.865
=	-0.21

EBIT per Share for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.85

Medincell (XPAR:MEDCL) EBIT per Share Explanation

EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.

Medincell EBIT per Share Related Terms

Thank you for viewing the detailed overview of Medincell's EBIT per Share provided by GuruFocus.com. Please click on the following links to see related term pages.

Medincell (XPAR:MEDCL) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medincell SA (XPAR:MEDCL) » Definitions » EBIT per Share

Comparable Companies

Traded in Other Exchanges

MEB:Germany

Address

3 rue des Freres Lumiere, Jacou, FRA, 34830

Website

https://www.medincell.com

Medincell SA is a technology-based pharmaceutical firm, aims to optimise the efficiency of medical treatments and make them accessible geographically. The company's product portfolio uses BEPO-patented technology to develop controlled, long-acting injectable medical treatments for a number of therapeutic fields. The firm has a single operating segment: ongoing research and development on processes that use biodegradable polymers to enable the controlled and prolonged release of the active principles of drugs into the human body and animals by means of injection.

Medincell (XPAR:MEDCL) Headlines

No Headlines